skip to main content
Guest
My Research
My Account
Sign out
Sign in
This feature requires javascript
Library Search
Find Databases
Browse Search
E-Journals A-Z
E-Books A-Z
Citation Linker
Help
Language:
English
Vietnamese
This feature required javascript
This feature requires javascript
Primo Search
All Library Resources
All
Course Materials
Course Materials
Search For:
Clear Search Box
Search in:
All Library Resources
Or hit Enter to replace search target
Or select another collection:
Search in:
All Library Resources
Search in:
Print Resources
Search in:
Digital Resources
Search in:
Online E-Resources
Advanced Search
Browse Search
This feature requires javascript
Search Limited to:
Search Limited to:
Resource type
criteria input
All items
Books
Articles
Images
Audio Visual
Maps
Graduate theses
Show Results with:
criteria input
that contain my query words
with my exact phrase
starts with
Show Results with:
Search type Index
criteria input
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
Show Results with:
in the title
Show Results with:
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
This feature requires javascript
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
Circulation research, 2015-03, Vol.116 (6), p.960-975
[Peer Reviewed Journal]
2015 American Heart Association, Inc. ;ISSN: 0009-7330 ;EISSN: 1524-4571 ;DOI: 10.1161/CIRCRESAHA.116.303587 ;PMID: 25767283
Full text available
Citations
Cited by
View Online
Details
Recommendations
Reviews
Times Cited
External Links
This feature requires javascript
Actions
Add to My Research
Remove from My Research
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
Author:
te Riet, Luuk
;
van Esch, Joep H.M
;
Roks, Anton J.M
;
van den Meiracker, Anton H
;
Danser, A.H Jan
Subjects:
Aldosterone - physiology
;
Angiotensin II Type 1 Receptor Blockers - therapeutic use
;
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
;
Animals
;
Antihypertensive Agents - pharmacology
;
Antihypertensive Agents - therapeutic use
;
Clinical Trials as Topic
;
Drug Evaluation, Preclinical
;
Drug Interactions
;
Drug Resistance
;
Drugs, Investigational - pharmacology
;
Drugs, Investigational - therapeutic use
;
Endothelium, Vascular - drug effects
;
Endothelium, Vascular - physiopathology
;
Female
;
Gonadal Steroid Hormones - physiology
;
Humans
;
Hyperaldosteronism - drug therapy
;
Hyperaldosteronism - genetics
;
Hyperaldosteronism - physiopathology
;
Hypertension - drug therapy
;
Hypertension - genetics
;
Hypertension - physiopathology
;
Ion Channels - physiology
;
Male
;
Mice
;
Mice, Knockout
;
Mice, Transgenic
;
Mineralocorticoid Receptor Antagonists - therapeutic use
;
Molecular Targeted Therapy
;
Precision Medicine
;
Renin-Angiotensin System - drug effects
;
Renin-Angiotensin System - genetics
;
Renin-Angiotensin System - physiology
;
Sex Characteristics
;
Sex Chromosomes
;
Therapeutic Equivalency
;
Vasoconstriction - drug effects
;
Vasoconstriction - physiology
Is Part Of:
Circulation research, 2015-03, Vol.116 (6), p.960-975
Description:
Blockers of the renin–angiotensin–aldosterone system (RAAS), that is, renin inhibitors, angiotensin (Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerstone in the treatment of hypertension. How exactly they exert their effect, in particular in patients with low circulating RAAS activity, also taking into consideration the so-called Ang II/aldosterone escape that often occurs after initial blockade, is still incompletely understood. Multiple studies have tried to find parameters that predict the response to RAAS blockade, allowing a personalized treatment approach. Consequently, the question should now be answered on what basis (eg, sex, ethnicity, age, salt intake, baseline renin, ACE or aldosterone, and genetic variance) a RAAS blocker can be chosen to treat an individual patient. Are all blockers equal? Does optimal blockade imply maximum RAAS blockade, for example, by combining ≥2 RAAS blockers or by simply increasing the dose of 1 blocker? Exciting recent investigations reveal a range of unanticipated extrarenal effects of aldosterone, as well as a detailed insight in the genetic causes of primary aldosteronism, and mineralocorticoid receptor blockers have now become an important treatment option for resistant hypertension. Finally, apart from the deleterious ACE-Ang II-Ang II type 1 receptor arm, animal studies support the existence of protective aminopeptidase A-Ang III-Ang II type 2 receptor and ACE2-Ang-(1 to 7)-Mas receptor arms, paving the way for multiple new treatment options. This review provides an update about all these aspects, critically discussing the many controversies and allowing the reader to obtain a full understanding of what we currently know about RAAS alterations in hypertension.
Publisher:
United States: American Heart Association, Inc
Language:
English
Identifier:
ISSN: 0009-7330
EISSN: 1524-4571
DOI: 10.1161/CIRCRESAHA.116.303587
PMID: 25767283
Source:
GFMER Free Medical Journals
MEDLINE
This feature requires javascript
This feature requires javascript
Back to results list
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript